Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1385074 | 0.99 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11SIGMAR1 | |
| SCHEMBL2929529 | 0.91 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1384642 | 0.91 | CSNK1E (0.45) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1384099 | 0.90 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL2926768 | 0.89 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1383826 | 0.88 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL2929523 | 0.88 | MAPK14 (0.39) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1386122 | 0.86 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL1385753 | 0.86 | SRC (0.43) | MAPK14MAPK13MAPK12MAPK11SIGMAR1 | |
| SCHEMBL1386983 | 0.86 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4814783-B2 | — | — | 2011-11-16 | — | — | JP | claimed |
| EP-1611131-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach y Compagnia S.A. (ES) | 2006-01-04 | — | — | EP | claimed |
| WO-2004076450-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach Y Compañia S.A. (ES) | 2004-09-10 | — | — | WO | claimed |
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | Poolbeg Pharma (UK) Limited (GB) | 2025-01-09 | — | — | US | disclosed |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | disclosed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011400-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885MAPK13 20/4885MAPK12 11/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK13 23/4885MAPK12 12/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885MAPK13 20/4885MAPK12 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.